158 related articles for article (PubMed ID: 33715378)
1. Discovery of Selective Pituitary Adenylate Cyclase 1 Receptor (PAC1R) Antagonist Peptides Potent in a Maxadilan/PACAP38-Induced Increase in Blood Flow Pharmacodynamic Model.
Hu E; Hong FT; Aral J; Long J; Piper DE; Poppe L; Andrews KL; Hager T; Davis C; Li H; Wong P; Gavva N; Shi L; Zhu DXD; Lehto SG; Xu C; Miranda LP
J Med Chem; 2021 Mar; 64(6):3427-3438. PubMed ID: 33715378
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism.
Wang J; Song X; Zhang D; Chen X; Li X; Sun Y; Li C; Song Y; Ding Y; Ren R; Harrington EH; Hu LA; Zhong W; Xu C; Huang X; Wang HW; Ma Y
Cell Res; 2020 May; 30(5):436-445. PubMed ID: 32047270
[TBL] [Abstract][Full Text] [Related]
3. PAC1R agonist maxadilan enhances hADSC viability and neural differentiation potential.
Guo X; Yu R; Xu Y; Lian R; Yu Y; Cui Z; Ji Q; Chen J; Li Z; Liu H; Chen J
J Cell Mol Med; 2016 May; 20(5):874-90. PubMed ID: 26798992
[TBL] [Abstract][Full Text] [Related]
4. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor.
Soares MB; Titus RG; Shoemaker CB; David JR; Bozza M
J Immunol; 1998 Feb; 160(4):1811-6. PubMed ID: 9469441
[TBL] [Abstract][Full Text] [Related]
5. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.
Vollesen ALH; Amin FM; Ashina M
Neurotherapeutics; 2018 Apr; 15(2):371-376. PubMed ID: 29464574
[TBL] [Abstract][Full Text] [Related]
6. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons.
Tatsuno I; Uchida D; Tanaka T; Saeki N; Hirai A; Saito Y; Moro O; Tajima M
Brain Res; 2001 Jan; 889(1-2):138-48. PubMed ID: 11166697
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PAC1 Receptor for Neurological and Metabolic Disorders.
Liao C; de Molliens MP; Schneebeli ST; Brewer M; Song G; Chatenet D; Braas KM; May V; Li J
Curr Top Med Chem; 2019; 19(16):1399-1417. PubMed ID: 31284862
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist.
Moro O; Wakita K; Ohnuma M; Denda S; Lerner EA; Tajima M
J Biol Chem; 1999 Aug; 274(33):23103-10. PubMed ID: 10438479
[TBL] [Abstract][Full Text] [Related]
9. Stimulatory effect of pituitary adenylate-cyclase activating polypeptide (PACAP) and its PACAP type I receptor (PAC1R) on prolactin synthesis in rat pituitary somatolactotroph GH3 cells.
Mijiddorj T; Kanasaki H; Purwana IN; Oride A; Miyazaki K
Mol Cell Endocrinol; 2011 Jun; 339(1-2):172-9. PubMed ID: 21539889
[TBL] [Abstract][Full Text] [Related]
10. Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway.
Svensjö E; Saraiva EM; Amendola RS; Barja-Fidalgo C; Bozza MT; Lerner EA; Teixeira MM; Scharfstein J
Microvasc Res; 2012 Mar; 83(2):185-93. PubMed ID: 22036674
[TBL] [Abstract][Full Text] [Related]
11. Maxadilan, the PAC1 receptor, and leishmaniasis.
Reddy VB; Li Y; Lerner EA
J Mol Neurosci; 2008 Nov; 36(1-3):241-4. PubMed ID: 18509762
[TBL] [Abstract][Full Text] [Related]
12. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
[TBL] [Abstract][Full Text] [Related]
13. Salivary gland homogenates of Lutzomyia longipalpis and its vasodilatory peptide maxadilan cause plasma leakage via PAC1 receptor activation.
Svensjö E; Saraiva EM; Bozza MT; Oliveira SM; Lerner EA; Scharfstein J
J Vasc Res; 2009; 46(5):435-46. PubMed ID: 19176972
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the PAC1R extracellular domain unifies a consensus fold for hormone recognition by class B G-protein coupled receptors.
Kumar S; Pioszak A; Zhang C; Swaminathan K; Xu HE
PLoS One; 2011; 6(5):e19682. PubMed ID: 21625560
[TBL] [Abstract][Full Text] [Related]
15. PACAP38 in human models of primary headaches.
Ashina H; Guo S; Vollesen ALH; Ashina M
J Headache Pain; 2017 Nov; 18(1):110. PubMed ID: 29453754
[TBL] [Abstract][Full Text] [Related]
16. The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin.
Banki E; Hajna Z; Kemeny A; Botz B; Nagy P; Bolcskei K; Toth G; Reglodi D; Helyes Z
Neuropharmacology; 2014 Oct; 85():538-47. PubMed ID: 24973707
[TBL] [Abstract][Full Text] [Related]
17. Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis.
Daniel PB; Kieffer TJ; Leech CA; Habener JF
J Biol Chem; 2001 Apr; 276(16):12938-44. PubMed ID: 11278585
[TBL] [Abstract][Full Text] [Related]
18. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist.
Moro O; Lerner EA
J Biol Chem; 1997 Jan; 272(2):966-70. PubMed ID: 8995389
[TBL] [Abstract][Full Text] [Related]
19. Cryo-EM structure of the human PAC1 receptor coupled to an engineered heterotrimeric G protein.
Kobayashi K; Shihoya W; Nishizawa T; Kadji FMN; Aoki J; Inoue A; Nureki O
Nat Struct Mol Biol; 2020 Mar; 27(3):274-280. PubMed ID: 32157248
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase 1 receptor internalization and endosomal signaling mediate the pituitary adenylate cyclase activating polypeptide-induced increase in guinea pig cardiac neuron excitability.
Merriam LA; Baran CN; Girard BM; Hardwick JC; May V; Parsons RL
J Neurosci; 2013 Mar; 33(10):4614-22. PubMed ID: 23467377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
